1. Home
  2. SYNX vs KPRX Comparison

SYNX vs KPRX Comparison

Compare SYNX & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silynxcom Ltd.

SYNX

Silynxcom Ltd.

HOLD

Current Price

$0.98

Market Cap

7.3M

Sector

N/A

ML Signal

HOLD

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

N/A

Current Price

$1.92

Market Cap

8.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SYNX
KPRX
Founded
2005
1998
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3M
8.0M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
SYNX
KPRX
Price
$0.98
$1.92
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
3.2M
28.5K
Earning Date
05-01-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$32.35
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$1.76
52 Week High
$2.15
$4.18

Technical Indicators

Market Signals
Indicator
SYNX
KPRX
Relative Strength Index (RSI) 43.40 42.19
Support Level $0.93 $1.76
Resistance Level $1.31 $2.20
Average True Range (ATR) 0.09 0.10
MACD -0.02 -0.01
Stochastic Oscillator 21.27 46.15

Price Performance

Historical Comparison
SYNX
KPRX

About SYNX Silynxcom Ltd.

Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: